v3.26.3
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Revenue:        
Collaboration and license $ 0 $ 0 $ 0 $ 400
Grant 0 452 78 1,450
Total revenues 0 452 78 1,850
Operating expenses:        
Research and development expense 15,623 13,802 55,517 43,345
General and administrative 9,378 7,716 25,216 23,271
Total operating expenses 25,001 21,518 80,733 66,616
Operating loss (25,001) (21,066) (80,655) (64,766)
Other income (expense):        
Interest income 1,202 1,548 3,331 5,311
Interest expense (1,991) 0 (2,843) 0
Gain on change in fair value of warrant liability 164 516 140 2,988
Gain (loss) on change in fair value of derivative liability 3,340 0 (1,195) 0
Gain (loss) on change in fair value of CVR liability 10,700 (16,900) 46,100 18,746
Other income (expense), net 114 0 237 (5)
Total other income (expense), net 13,529 (14,836) 45,770 27,040
Net loss (11,472) (35,902) (34,885) (37,726)
Other comprehensive (loss) income:        
Foreign currency translation adjustment (13) (10) (45) 34
Total comprehensive loss (11,485) (35,912) (34,930) (37,692)
Net loss $ (11,472) $ (35,902) $ (34,885) $ (37,726)
Net loss per share allocable to common stockholders:        
Basic (in dollars per share) $ (0.38) $ (1.38) $ (1.21) $ (1.45)
Diluted (in dollars per share) $ (0.38) $ (1.38) $ (1.21) $ (1.45)
Weighted-average common shares outstanding:        
Basic (in shares) 30,309,295 26,002,892 28,894,967 25,962,302
Diluted (in shares) 30,309,295 26,002,892 28,894,967 25,962,302